aldosterone and Disease Exacerbation studies

Research Excerpts

Excerpt	Relevance	Reference
"73 m(2) and proteinuria with protein greater than 500 mg/g of creatinine on treatment with losartan, 100 mg/d, for longer than 6 months were screened in National Taiwan University Hospital."	9.13	Effect of pentoxifylline in addition to losartan on proteinuria and GFR in CKD: a 12-month randomized trial. ( Chen, YM; Chiang, WC; Lin, SL; Tsai, TJ; Wu, KD, 2008)
"This Phase II study was designed to determine the efficacy and tolerability of vorozole (R83842), a new nonsteroidal aromatase inhibitor, in postmenopausal women with advanced breast cancer in progression being treated with tamoxifen, and to correlate these effects with the hormonal profile and plasma drug levels."	9.08	Phase II study of vorozole (R83842), a new aromatase inhibitor, in postmenopausal women with advanced breast cancer in progression on tamoxifen. ( Ambus, U; Bruynseels, J; Clark, RM; Crump, M; De Coster, R; Goss, PE; Tye, LM; Wadden, NA; Walde, D; Weizel, HA, 1995)
"It has been proposed that worsening of heart failure with dihydropyridines, such as nicardipine, is related to the activation of the neuroendocrine system."	9.08	Clinical and neurohormonal effects of nicardipine hydrochloride in patients with severe chronic heart failure receiving angiotensin-converting enzyme inhibitor therapy. ( Benatar, D; Gheorghiade, M; Hall, V; Reddy, S, 1998)
"Tachycardic pigs given furosemide had significant acceleration of both contractile and metabolic features of CHF, including left ventricular systolic dysfunction, elevated serum aldosterone levels, and altered calcium handling in a controlled experimental model of heart failure."	7.72	Furosemide and the progression of left ventricular dysfunction in experimental heart failure. ( Haigney, MC; Hanlon, SU; McCurley, JM; Michalski, M; Wedam, EF; Wei, SK, 2004)
"Adrenomedullin (AM) is expressed in cardiac tissue, and plasma AM levels increase in patients with acute myocardial infarction (MI)."	7.72	Adrenomedullin administration immediately after myocardial infarction ameliorates progression of heart failure in rats. ( Asada, Y; Cao, Y; Eto, T; Imamura, T; Kangawa, K; Kato, J; Kitamura, K; Marutsuka, K; Nakamura, R; Onitsuka, H, 2004)
"Aldosterone was measured at baseline, brain natriuretic peptide and procollagen type III amino-terminal peptide (PIIINP) at baseline and at 6 months."	6.73	Baseline characteristics of patients recruited in the AREA IN-CHF study (Antiremodelling Effect of Aldosterone Receptors Blockade with Canrenone in Mild Chronic Heart Failure). ( Boccanelli, A; Cacciatore, G; Clemenza, F; De Maria, R; de Simone, G; Di Lenarda, A; Gavazzi, A; Gonzini, L; Latini, R; Maggioni, AP; Masson, S; Mureddu, GF; Porcu, M; Vanasia, M, 2007)
"Aldosterone has been linked with obesity, metabolic syndrome (MetS), pro-inflammatory, and prothrombotic states; however, most studies relate these indicators with primary aldosteronism (PA), excluding non-PA patients."	5.51	The Aldosterone/Renin Ratio Predicts Cardiometabolic Disorders in Subjects Without Classic Primary Aldosteronism. ( Allende, F; Barros, ER; Baudrand, R; Campino, C; Carvajal, C; Fardella, CE; Fuentes, CA; García, H; Kalergis, AM; Martínez-Aguayo, A; Olmos, R; Solari, S; Tapia-Castillo, A; Vecchiola, A, 2019)
"Primary aldosteronism (PA) is associated with a higher incidence of cardiovascular events, probably through mineralocorticoid receptor (MR)-dependent endothelial cell dysfunction, in comparison with essential hypertension (EH)."	5.37	Endothelial progenitor cells in primary aldosteronism: a biomarker of severity for aldosterone vasculopathy and prognosis. ( Chen, JW; Chen, YL; Huang, PH; Kuo, CC; Kuo, YS; Lee, BC; Liang, CJ; Lin, SJ; Lin, SL; Lin, YH; Lo, SC; Sun, YY; Tsai, CT; Wu, EL; Wu, KD; Wu, VC, 2011)
"To measure the effects of hyperinsulinemia on serum electrolyte status and associated hormones, and on serum free fatty acid (FFA) concentrations, in patients with essential hypertension."	5.31	Serum aldosterone changes during hyperinsulinemia are correlated to body mass index and insulin sensitivity in patients with essential hypertension. ( Haenni, A; Lind, L; Lithell, H; Reneland, R, 2001)
"73 m(2) and proteinuria with protein greater than 500 mg/g of creatinine on treatment with losartan, 100 mg/d, for longer than 6 months were screened in National Taiwan University Hospital."	5.13	Effect of pentoxifylline in addition to losartan on proteinuria and GFR in CKD: a 12-month randomized trial. ( Chen, YM; Chiang, WC; Lin, SL; Tsai, TJ; Wu, KD, 2008)
"This Phase II study was designed to determine the efficacy and tolerability of vorozole (R83842), a new nonsteroidal aromatase inhibitor, in postmenopausal women with advanced breast cancer in progression being treated with tamoxifen, and to correlate these effects with the hormonal profile and plasma drug levels."	5.08	Phase II study of vorozole (R83842), a new aromatase inhibitor, in postmenopausal women with advanced breast cancer in progression on tamoxifen. ( Ambus, U; Bruynseels, J; Clark, RM; Crump, M; De Coster, R; Goss, PE; Tye, LM; Wadden, NA; Walde, D; Weizel, HA, 1995)
"It has been proposed that worsening of heart failure with dihydropyridines, such as nicardipine, is related to the activation of the neuroendocrine system."	5.08	Clinical and neurohormonal effects of nicardipine hydrochloride in patients with severe chronic heart failure receiving angiotensin-converting enzyme inhibitor therapy. ( Benatar, D; Gheorghiade, M; Hall, V; Reddy, S, 1998)
"Studies in animals and humans show that increased tissue acidity raises the renal levels of endothelin, angiotensin II, aldosterone, and ammoniagenesis, thereby worsening renal fibrosis and causing progression of CKD."	4.98	Retarding progression of chronic kidney disease: use of modalities that counter acid retention. ( Kraut, JA; Madias, NE, 2018)
"Tachycardic pigs given furosemide had significant acceleration of both contractile and metabolic features of CHF, including left ventricular systolic dysfunction, elevated serum aldosterone levels, and altered calcium handling in a controlled experimental model of heart failure."	3.72	Furosemide and the progression of left ventricular dysfunction in experimental heart failure. ( Haigney, MC; Hanlon, SU; McCurley, JM; Michalski, M; Wedam, EF; Wei, SK, 2004)
"Changes induced by intense physical exercise on quantitative and qualitative proteinuria were evaluated in basal conditions and after 10 days of ramipril therapy in 10 patients with IgA nephropathy, normal glomerular filtration rate (GFR), proteinuria between 0."	3.72	Can young adult patients with proteinuric IgA nephropathy perform physical exercise? ( Andreucci, M; Caglioti, A; Cianfrone, P; Comi, N; Fuiano, G; Fuiano, L; Mancuso, D; Marino, F; Mazza, G; Zamboli, P, 2004)
"Adrenomedullin (AM) is expressed in cardiac tissue, and plasma AM levels increase in patients with acute myocardial infarction (MI)."	3.72	Adrenomedullin administration immediately after myocardial infarction ameliorates progression of heart failure in rats. ( Asada, Y; Cao, Y; Eto, T; Imamura, T; Kangawa, K; Kato, J; Kitamura, K; Marutsuka, K; Nakamura, R; Onitsuka, H, 2004)
"Primary aldosteronism (PA) is an established cause of hypertension, whereas high-normal serum aldosterone levels have been linked to an increased risk for hypertension."	2.78	Evidence of primary aldosteronism in a predominantly female cohort of normotensive individuals: a very high odds ratio for progression into arterial hypertension. ( Chrousos, GP; Gouli, A; Kaltsas, G; Markou, A; Mitsakis, K; Papanastasiou, L; Pappa, T; Piaditis, GP; Prevoli, A; Tsiavos, V; Tsounas, P; Zografos, G, 2013)
"Aldosterone was measured at baseline, brain natriuretic peptide and procollagen type III amino-terminal peptide (PIIINP) at baseline and at 6 months."	2.73	Baseline characteristics of patients recruited in the AREA IN-CHF study (Antiremodelling Effect of Aldosterone Receptors Blockade with Canrenone in Mild Chronic Heart Failure). ( Boccanelli, A; Cacciatore, G; Clemenza, F; De Maria, R; de Simone, G; Di Lenarda, A; Gavazzi, A; Gonzini, L; Latini, R; Maggioni, AP; Masson, S; Mureddu, GF; Porcu, M; Vanasia, M, 2007)
"Hypokalemia is closely linked with the pathophysiology of primary aldosteronism (PA)."	2.66	Hypokalemia and the Prevalence of Primary Aldosteronism. ( Beuschlein, F; Gruber, S, 2020)
"Aldosterone is a mineralocorticoid hormone that participates in the regulation of electrolyte balance, blood pressure, and tissue remodeling."	2.61	Endothelial Dysfunction in Primary Aldosteronism. ( Chen, ZW; Chou, CH; Hung, CS; Liao, CW; Lin, YH; Pan, CT; Tsai, CH; Wu, VC, 2019)
"19."	2.53	Mineralocorticoid Receptor Antagonists in End-Stage Renal Disease: Efficacy and Safety. ( Bomback, AS, 2016)
"Aldosterone plays a significant role in the pathogenesis of arterial hypertension and renal disease."	2.44	Aldosterone and progression of renal disease. ( Wenzel, U, 2008)
"More than 80% of patients with type 2 diabetes mellitus develop hypertension, and approx."	2.44	Vascular inflammation in hypertension and diabetes: molecular mechanisms and therapeutic interventions. ( Savoia, C; Schiffrin, EL, 2007)
"End-stage renal disease (ESRD) comprises an enormous public health burden, with an incidence and prevalence that are increasingly on the rise."	2.41	Aldosterone as a mediator of progressive renal dysfunction: evolving perspectives. ( Epstein, M, 2001)
"Hypertension is a major risk factor for progressive renal disease."	2.41	Aldosterone and the hypertensive kidney: its emerging role as a mediator of progressive renal dysfunction: a paradigm shift. ( Epstein, M, 2001)
"In patients with CKD, untreated chronic metabolic acidosis often leads to an accelerated reduction in GFR."	1.56	Mechanisms of Metabolic Acidosis-Induced Kidney Injury in Chronic Kidney Disease. ( Bushinsky, DA; Buysse, JM; Wesson, DE, 2020)
"Aldosterone has been proved a risk factor of fibrosis and inflammation."	1.51	Aldosterone induced up-expression of ICAM-1 and ET-1 in pancreatic islet endothelium may associate with progression of T2D. ( Chen, L; Cui, C; Guo, X; He, Q; Hou, X; Hu, H; Liu, F; Qin, J; Song, J; Wang, J; Yan, F, 2019)
"Objective- Pulmonary arterial hypertension is characterized by progressive pulmonary vascular remodeling and persistently elevated mean pulmonary artery pressures and pulmonary vascular resistance."	1.51	Transthoracic Pulmonary Artery Denervation for Pulmonary Arterial Hypertension. ( Huang, Y; Jing, ZC; Li, J; Liu, YW; Meng, J; Pan, HZ; Wang, PH; Xiang, L; Yang, J; Zhang, H; Zhang, XL, 2019)
"Aldosterone has been linked with obesity, metabolic syndrome (MetS), pro-inflammatory, and prothrombotic states; however, most studies relate these indicators with primary aldosteronism (PA), excluding non-PA patients."	1.51	The Aldosterone/Renin Ratio Predicts Cardiometabolic Disorders in Subjects Without Classic Primary Aldosteronism. ( Allende, F; Barros, ER; Baudrand, R; Campino, C; Carvajal, C; Fardella, CE; Fuentes, CA; García, H; Kalergis, AM; Martínez-Aguayo, A; Olmos, R; Solari, S; Tapia-Castillo, A; Vecchiola, A, 2019)
"Mean aldosterone levels were highest in the TT group and lowest in CC group (p = 0."	1.48	Modulation of aldosterone levels by aldosterone synthase promoter polymorphism and association with eGFR decline in patients with chronic kidney disease. ( Gu, Y; Hao, C; Lai, L; Qian, J; Shi, H; Yan, M; Zhong, J, 2018)
"Aldosterone levels were positively associated with CKD stage, and were inversely correlated with circulating α-klotho levels."	1.48	Circulating α-Klotho is Related to Plasma Aldosterone and Its Follow-Up Change Predicts CKD Progression. ( Cheng, P; Gu, Y; Hao, C; Lai, L; Qian, J; Shi, H; Yan, M; Zhong, J, 2018)
"Aldosterone is a mineralocorticoid hormone produced in the adrenal glands and plays a role in the maintenance of key ion pumps, including the Na-K(+)-Cl co-transporter 1 or NKCC1, which is involved in homeostatic maintenance of the endocochlear potential."	1.43	Long-term treatment with aldosterone slows the progression of age-related hearing loss. ( Ding, B; Frisina, RD; Halonen, J; Hinton, AS; Walton, JP; Zhu, X, 2016)
"Autosomal recessive polycystic kidney disease is a genetic disorder characterized by the development of renal cysts of tubular epithelial cell origin."	1.42	Impaired epithelial Na+ channel activity contributes to cystogenesis and development of autosomal recessive polycystic kidney disease in PCK rats. ( Ilatovskaya, DV; Levchenko, V; Palygin, O; Pavlov, TS; Staruschenko, A, 2015)
"Hypertension was less marked in IFNγKO-aldosterone mice than in WT-aldosterone mice (127 ± 5 vs."	1.38	Interferon-γ ablation exacerbates myocardial hypertrophy in diastolic heart failure. ( Baid, S; Garcia, AG; Heo, J; Murthy, NR; Ouchi, N; Sam, F; Wilson, RM, 2012)
"Primary aldosteronism (PA) is associated with a higher incidence of cardiovascular events, probably through mineralocorticoid receptor (MR)-dependent endothelial cell dysfunction, in comparison with essential hypertension (EH)."	1.37	Endothelial progenitor cells in primary aldosteronism: a biomarker of severity for aldosterone vasculopathy and prognosis. ( Chen, JW; Chen, YL; Huang, PH; Kuo, CC; Kuo, YS; Lee, BC; Liang, CJ; Lin, SJ; Lin, SL; Lin, YH; Lo, SC; Sun, YY; Tsai, CT; Wu, EL; Wu, KD; Wu, VC, 2011)
"Although non-alcoholic steatohepatitis (NASH) may progress to cirrhosis and hepatocellular carcinoma (HCC), no effective therapeutic modalities have been fully established yet."	1.36	Selective aldosterone blocker ameliorates the progression of non-alcoholic steatohepatitis in rats. ( Aihara, Y; Fukui, H; Ikenaka, Y; Kaji, K; Kawaratani, H; Kitade, M; Namisaki, T; Noguchi, R; Shirai, Y; Tsujimoto, T; Yamazaki, M; Yanase, K; Yoshii, J; Yoshiji, H, 2010)
"Diabetic pregnancy is associated with lower levels of PRA and ANP compared to non-diabetic pregnancy."	1.33	Vasoactive mediators and retinopathy during type 1 diabetic pregnancy. ( Hiilesmaa, VK; Immonen, IJ; Kaaja, RJ; Loukovaara, S; Nicholls, G; Yandle, TG, 2005)
"Thus, aldosteronism is associated with an activation of circulating immune cells induced by iterations in PBMC divalent cations and transduced by oxidative/nitrosative stress."	1.32	Aldosteronism and peripheral blood mononuclear cell activation: a neuroendocrine-immune interface. ( Ahokas, RA; Bhattacharya, SK; Gerling, IC; Herring, PA; Lu, L; Postlethwaite, AE; Sun, Y; Warrington, KJ; Weber, KT; Wodi, LA, 2003)
"Aldosterone promotes nephrosclerosis in several rat models, whereas aldosterone receptor antagonism blunts the effect of activation of the renin-angiotensin-aldosterone system (RAAS) on nephrosclerosis, independent of effects on blood pressure."	1.31	Aldosterone modulates plasminogen activator inhibitor-1 and glomerulosclerosis in vivo. ( Brown, NJ; Donnert, E; Fogo, AB; Freeman, M; Ma, L; Nakamura, I; Nakamura, S; Vaughan, DE, 2000)
"To measure the effects of hyperinsulinemia on serum electrolyte status and associated hormones, and on serum free fatty acid (FFA) concentrations, in patients with essential hypertension."	1.31	Serum aldosterone changes during hyperinsulinemia are correlated to body mass index and insulin sensitivity in patients with essential hypertension. ( Haenni, A; Lind, L; Lithell, H; Reneland, R, 2001)

Research

Studies (92)

Authors

Clinical Trials (8)

Trial Overview

Trial Outcomes

Albuminuria

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	6 (6.52)	18.2507
2000's	39 (42.39)	29.6817
2010's	41 (44.57)	24.3611
2020's	6 (6.52)	2.80

Authors	Studies
Verma, A	1
Vaidya, A	1
Subudhi, S	1
Waikar, SS	1
Williams, C	1
Han, D	1
Takagi, H	1
Fordyce, CB	1
Sellers, S	1
Blanke, P	1
Lin, FY	1
Shaw, LJ	1
Lee, SE	1
Andreini, D	1
Al-Mallah, MH	1
Budoff, MJ	1
Cademartiri, F	1
Chinnaiyan, K	1
Choi, JH	1
Conte, E	1
Marques, H	1
de Araújo Gonçalves, P	1
Gottlieb, I	1
Hadamitzky, M	1
Maffei, E	1
Pontone, G	1
Shin, S	1
Kim, YJ	1
Lee, BK	1
Chun, EJ	1
Sung, JM	1
Virmani, R	1
Samady, H	1
Stone, PH	1
Berman, DS	1
Narula, J	1
Bax, JJ	1
Leipsic, JA	1
Chang, HJ	1
Chen, ZW	1
Tsai, CH	1
Pan, CT	1
Chou, CH	1
Liao, CW	1
Hung, CS	1
Wu, VC	2
Lin, YH	2
Wesson, DE	1
Buysse, JM	1
Bushinsky, DA	1
Gruber, S	1
Beuschlein, F	1
Handgriff, L	1
Adolf, C	1
Heinrich, DA	1
Braun, L	1
Nirschl, N	1
Sturm, L	1
Ladurner, R	1
Ricke, J	1
Seidensticker, M	1
Bidlingmaier, M	2
Reincke, M	2
Chan, EY	1
Ma, AL	1
Tullus, K	1
Maiolino, G	1
Rossitto, G	1
Bisogni, V	1
Cesari, M	1
Seccia, TM	1
Plebani, M	1
Rossi, GP	1
Karashima, S	1
Kometani, M	1
Tsujiguchi, H	1
Asakura, H	1
Nakano, S	1
Usukura, M	1
Mori, S	1
Ohe, M	1
Sawamura, T	1
Okuda, R	1
Hara, A	1
Takamura, T	2
Yamagishi, M	1
Nakamura, H	1
Takeda, Y	1
Yoneda, T	1
Hong, AR	1
Kim, JH	1
Park, KS	1
Kim, KY	1
Lee, JH	1
Kong, SH	1
Lee, SY	1
Shin, CS	1
Kim, SW	1
Kim, SY	1
Kraut, JA	1
Madias, NE	1
Roucher-Boulez, F	1
Brac de la Perriere, A	1
Jacquez, A	1
Chau, D	1
Guignat, L	1
Vial, C	1
Morel, Y	1
Nicolino, M	1
Raverot, G	1
Pugeat, M	1
Qian, J	2
Zhong, J	2
Yan, M	2
Cheng, P	1
Shi, H	2
Hao, C	2
Gu, Y	2
Lai, L	2
Mwasongwe, SE	1
Young, B	1
Bidulescu, A	1
Sims, M	1
Correa, A	1
Musani, SK	1
Vecchiola, A	1
Fuentes, CA	1
Barros, ER	1
Martínez-Aguayo, A	1
García, H	1
Allende, F	1
Solari, S	1
Olmos, R	1
Carvajal, C	1
Tapia-Castillo, A	1
Campino, C	1
Kalergis, AM	1
Baudrand, R	1
Fardella, CE	1
Resic, N	1
Durak-Nalbantic, A	1
Dzubur, A	1
Begic, A	1
Begic, E	1
Huang, Y	1
Liu, YW	1
Pan, HZ	1
Zhang, XL	1
Li, J	1
Xiang, L	1
Meng, J	1
Wang, PH	1
Yang, J	1
Jing, ZC	1
Zhang, H	1
Wang, J	1
Hu, H	1
Song, J	1
Yan, F	1
Qin, J	1
Guo, X	1
Cui, C	1
He, Q	1
Hou, X	1
Liu, F	1
Chen, L	1
Markou, A	1
Pappa, T	1
Kaltsas, G	1
Gouli, A	1
Mitsakis, K	1
Tsounas, P	1
Prevoli, A	1
Tsiavos, V	1
Papanastasiou, L	1
Zografos, G	1
Chrousos, GP	1
Piaditis, GP	1
Tiberio, L	1
Nascimbeni, R	1
Villanacci, V	1
Casella, C	1
Fra, A	1
Vezzoli, V	1
Furlan, L	1
Meyer, G	1
Parrinello, G	1
Baroni, MD	1
Salerni, B	1
Schiaffonati, L	1
McGraw, AP	1
McCurley, A	1
Preston, IR	1
Jaffe, IZ	1
Fernández-Juárez, G	1
Luño, J	1
Barrio, V	1
de Vinuesa, SG	1
Praga, M	1
Goicoechea, M	1
Lahera, V	1
Casas, L	1
Oliva, J	1
Dai, Z	1
Yu, S	1
Zhao, Q	1
Meng, Y	1
He, H	1
Tang, Y	1
Wang, X	2
Xiao, J	1
Huang, C	1
Tanaka, K	1
Wilson, RM	2
Essick, EE	1
Duffen, JL	1
Scherer, PE	1
Ouchi, N	2
Sam, F	2
Pavlov, TS	1
Levchenko, V	1
Ilatovskaya, DV	1
Palygin, O	1
Staruschenko, A	1
Torres, VE	1
Abebe, KZ	1
Chapman, AB	1
Schrier, RW	1
Braun, WE	1
Steinman, TI	1
Winklhofer, FT	1
Brosnahan, G	1
Czarnecki, PG	1
Hogan, MC	1
Miskulin, DC	1
Rahbari-Oskoui, FF	1
Grantham, JJ	1
Harris, PC	1
Flessner, MF	1
Moore, CG	1
Perrone, RD	1
Zhou, J	1
Shaikh, LH	1
Neogi, SG	1
McFarlane, I	1
Zhao, W	1
Figg, N	1
Brighton, CA	1
Maniero, C	1
Teo, AE	1
Azizan, EA	1
Brown, MJ	1
Bomback, AS	1
Halonen, J	1
Hinton, AS	1
Frisina, RD	1
Ding, B	1
Zhu, X	1
Walton, JP	1
Then, C	1
Rottenkolber, M	1
Lechner, A	1
Meisinger, C	1
Heier, M	1
Koenig, W	1
Peters, A	1
Rathmann, W	1
Seissler, J	1
Ruilope, LM	1
Lin, SL	2
Chen, YM	1
Chiang, WC	1
Wu, KD	2
Tsai, TJ	1
Kurita, T	1
Onishi, K	1
Dohi, K	1
Fujimoto, N	1
Tanigawa, T	1
Imanaka-Yoshida, K	1
Wada, H	1
Nobori, T	1
Ito, M	1
Cortinovis, M	1
Perico, N	1
Cattaneo, D	1
Remuzzi, G	1
Ku, E	2
Campese, VM	2
Kooter, AJ	1
Smulders, YM	1
Gkizas, SI	1
Apostolakis, E	1
Pagoulatou, E	1
Mavrilas, D	1
Papachristou, DJ	1
Koletsis, E	1
Papalois, A	1
Papadaki, H	1
Alexopoulos, D	1
Edelmann, F	1
Schmidt, AG	1
Gelbrich, G	1
Binder, L	1
Herrmann-Lingen, C	1
Halle, M	1
Hasenfuss, G	1
Wachter, R	1
Pieske, B	1
Lu, Y	1
Noguchi, R	1
Yoshiji, H	1
Ikenaka, Y	1
Kaji, K	1
Shirai, Y	1
Aihara, Y	1
Yamazaki, M	1
Namisaki, T	1
Kitade, M	1
Yoshii, J	1
Yanase, K	1
Kawaratani, H	1
Tsujimoto, T	1
Fukui, H	1
Sahni, V	1
Rosa, RM	1
Batlle, D	1
Lymperopoulos, A	1
Rengo, G	1
Zincarelli, C	1
Kim, J	1
Koch, WJ	1
Bantis, C	1
Heering, PJ	1
Siekierka-Harreis, M	1
Kouri, NM	1
Schwandt, C	1
Rump, LC	1
Ivens, K	1
Mangoni, AA	1
Knights, KM	1
Lo, SC	1
Chen, YL	1
Huang, PH	1
Tsai, CT	1
Liang, CJ	1
Kuo, CC	1
Kuo, YS	1
Lee, BC	1
Wu, EL	1
Sun, YY	1
Chen, JW	1
Lin, SJ	1
Lian, M	1
Hewitson, TD	1
Wigg, B	1
Samuel, CS	1
Chow, F	1
Becker, GJ	1
Zhou, X	1
Crook, MF	1
Sharif-Rodriguez, W	1
Zhu, Y	1
Ruben, Z	1
Pan, Y	1
Urosevic-Price, O	1
Wang, L	1
Flattery, AM	1
Forrest, G	1
Szeto, D	1
Zhao, H	1
Roy, S	1
Forrest, MJ	1
Ronconi, V	1
Turchi, F	1
Appolloni, G	1
di Tizio, V	1
Boscaro, M	1
Giacchetti, G	1
Shavit, L	1
Lifschitz, MD	1
Epstein, M	4
Garcia, AG	1
Heo, J	1
Murthy, NR	1
Baid, S	1
Huang, BS	1
Ahmad, M	1
White, RA	1
Marc, Y	1
Llorens-Cortes, C	1
Leenen, FH	1
Ibrahim, HN	2
Hostetter, TH	2
Konstam, MA	1
Persu, A	1
Panos, J	1
Michelis, MF	1
DeVita, MV	1
Lavie, RH	1
Wilkes, BM	1
Makarevich, AE	1
Domanski, M	1
Norman, J	1
Pitt, B	1
Haigney, M	1
Hanlon, S	1
Peyster, E	1
Ahokas, RA	1
Warrington, KJ	1
Gerling, IC	1
Sun, Y	1
Wodi, LA	1
Herring, PA	1
Lu, L	1
Bhattacharya, SK	1
Postlethwaite, AE	1
Weber, KT	1
Piano, MR	1
Prasun, M	1
Folkeringa, RJ	1
Pinto, YM	1
Crijns, HJ	1
Hollenberg, NK	1
Nakamura, R	1
Kato, J	1
Kitamura, K	1
Onitsuka, H	1
Imamura, T	1
Cao, Y	1
Marutsuka, K	1
Asada, Y	1
Kangawa, K	1
Eto, T	1
Fuiano, G	1
Mancuso, D	1
Cianfrone, P	1
Comi, N	1
Mazza, G	1
Marino, F	1
Fuiano, L	1
Zamboli, P	1
Caglioti, A	1
Andreucci, M	1
McCurley, JM	1
Hanlon, SU	1
Wei, SK	1
Wedam, EF	1
Michalski, M	1
Haigney, MC	1
Loukovaara, S	1
Immonen, IJ	1
Yandle, TG	1
Nicholls, G	1
Hiilesmaa, VK	1
Kaaja, RJ	1
Terada, Y	1
Kobayashi, T	1
Kuwana, H	1
Tanaka, H	1
Inoshita, S	1
Kuwahara, M	1
Sasaki, S	1
Passino, C	1
Poletti, R	1
Bramanti, F	1
Prontera, C	1
Clerico, A	1
Emdin, M	1
Oddo, EM	1
de Luca Sarobe, V	1
Krmar, R	1
Periz, GA	1
Herrera, H	1
Martín, RS	1
Ibarra, FR	1
Arrizurieta, EE	1
Laski, ME	1
Sabatini, S	1
Hayashi, K	1
Wakino, S	1
Sugano, N	1
Ozawa, Y	1
Homma, K	1
Saruta, T	1
Savoia, C	1
Schiffrin, EL	1
Burnett, JC	1
Boccanelli, A	1
Cacciatore, G	1
Mureddu, GF	1
de Simone, G	1
Clemenza, F	1
De Maria, R	1
Di Lenarda, A	1
Gavazzi, A	1
Latini, R	1
Masson, S	1
Porcu, M	1
Vanasia, M	1

Trial	Phase	Enrollment	Study Type	Start Date	Status
Prospective Assessment of The Prevalence of Primary Aldosteronism in Hypertensive Patients Presenting With Atrial Flutter or Fibrillation[NCT01267747]		411 participants (Actual)	Observational	2015-01-31	Completed
HALT Progression of Polycystic Kidney Disease Study B[NCT01885559]	Phase 3	486 participants (Actual)	Interventional	2006-01-31	Completed
Renal Ageing-sarcopenia Network: a Combined Genetic, Immunological and Psychological Approach to Dissect Frailty[NCT04630132]		1,500 participants (Anticipated)	Observational	2017-03-25	Recruiting
[NCT01832558]		24 participants (Anticipated)	Interventional	2012-11-30	Recruiting
[NCT00000516]	Phase 3	0 participants	Interventional	1985-07-31	Completed
Aquapheresis Versus Intravenous Diuretics and Hospitalizations for Heart Failure (AVOID-HF)[NCT01474200]		224 participants (Actual)	Interventional	2012-01-31	Terminated (stopped due to Closed due to patient recruitment challenges. No interim analyses were completed; study closure was not related to any concerns about safety or futility.)
Phase 3 Study Of Antiremodeling Effect Of Aldosterone Receptors Blockade With Canrenone In Mild Chronic Heart Failure[NCT00403910]	Phase 3	500 participants	Interventional	2002-09-30	Completed
[NCT00005757]		293 participants (Actual)	Observational	1997-09-30	Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Annual percent change in 24 hour urine albumin, centrally processed. Data from multiple years were analyzed with the primary focus on the change over time for the measure (from the slope of the model). The measure presented is the average annual percent change across the 8 years. (NCT01885559)
Timeframe: up to 8 years (annually assessed)

Aldosterone

Intervention	annual percent change (Mean)
ACE-I + Placebo	7.5
ACE-I + ARB	7.3

Annual percent change in urinary aldosterone, centrally processed measure. Data from multiple years were analyzed with the primary focus on the change over time for the measure (from the slope for time from the model). The measure presented is the average annual percent change across the 8 years. (NCT01885559)
Timeframe: up at 8 years (annually assessed)

Back or Flank Pain

Intervention	annual percent change (Mean)
ACE-I + Placebo	-8.8
ACE-I + ARB	-10.2

Report of back or flank pain since the last visit (yes or no) (NCT01885559)
Timeframe: 48 months

Cardiovascular Hospitalizations

Intervention	percentage of participants at 48 months (Number)
ACE-I + Placebo	43
ACE-I + ARB	46

Cause-specific hospitalizations (cardiovascular) (NCT01885559)
Timeframe: up to 8 years

Hospitalizations

Number of Participants With 50% Reduction of Baseline eGFR, End Stage Renal Disease (ESRD, Initiation of Dialysis or Preemptive Transplant), or Death.

Intervention	events (Number)
ACE-I + Placebo	29
ACE-I + ARB	16

Intervention	events (Number)
ACE-I + Placebo	173
ACE-I + ARB	136

(NCT01885559)
Timeframe: Patients followed for 5-8 years with average of 6.5 years follow up

Quality of Life Mental Component Summary

Intervention	participants (Number)
ACE-I + Placebo	116
ACE-I + ARB	115

Short Form-36 Quality of Life Mental Component Summary ranges from 0 (worst possible outcome) to 100 (best possible outcome). Data from multiple years were analyzed with the primary focus on the change over time for the measure (from the slope for time from the model). The measure presented is the average annual change across the 8 years. (NCT01885559)
Timeframe: up to 8 years (annually assessed)

Quality of Life Physical Component Summary

Intervention	units on a scale per year (Mean)
ACE-I + Placebo	-0.031
ACE-I + ARB	-0.079

Short Form-36 Quality of Life Physical Component Summary ranges from 0 (worst possible outcome) to 100 (best possible outcome). Data from multiple years were analyzed with the primary focus on the change over time for the measure (from the slope for time from the model). The measure presented is the average annual change across the 8 years. (NCT01885559)
Timeframe: up to 8 years (annually assessed)

EFFICACY: Freedom From Congestion

Intervention	units on a scale per year (Mean)
ACE-I + Placebo	-0.64
ACE-I + ARB	-0.68

Defined as jugular venous distention of < or equal to 8 cm, with no orthopnea, and with trace peripheral edema or no edema at hospital discharge (NCT01474200)
Timeframe: Index Hospitalization, an average of 8 days

EFFICACY: Net Fluid Removed During the Index Hospitalization

Intervention	Participants (Number)
Aquapheresis (AQ) - Isolated Veno-venous Ultrafiltration	40
IV Loop Diuretics (LD)	46

AQ-Fluid removed by AQ plus urine voided minus fluid intake versus urine voided minus fluid intake with the IV diuretics. (NCT01474200)
Timeframe: Index Hospitalization, an average of 8 days

EFFICACY: Time to Freedom From Congestion

Intervention	mL (Mean)
Aquapheresis (AQ) - Isolated Veno-venous Ultrafiltration	12921
IV Loop Diuretics (LD)	8907

Time from hospital admission to time patient is free of congestion in the hospital. Freedom from congestion is defined as jugular venous distention of < or equal to 8 cm, with no orthopnea and with trace peripheral edema or no edema. Measurement taken every 24 hours after treatment initiation. (NCT01474200)
Timeframe: Index Hospitalization, an average of 8 days

EFFICACY: Total Fluid Removed During the Index Hospitalization

Intervention	Days (Mean)
Aquapheresis (AQ) - Isolated Veno-venous Ultrafiltration	5.28
IV Loop Diuretics (LD)	3.86

AQ-Fluid removed by AQ plus urine voided versus urine voided when treated with IV diuretics (NCT01474200)
Timeframe: Index Hospitalization, an average of 8 days

EFFICACY: Total Weight Loss During the Index Hospitalization

Intervention	mL (Mean)
Aquapheresis (AQ) - Isolated Veno-venous Ultrafiltration	18700
IV Loop Diuretics (LD)	14043

Weight at hospital discharge minus weight at hospital admission. Negative mean values indicate weight loss. (NCT01474200)
Timeframe: Index Hospitalization, an average of 8 days

EFFICACY: Weight Loss at 72 Hours After Initiation of Treatment

Intervention	lbs (Mean)
Aquapheresis (AQ) - Isolated Veno-venous Ultrafiltration	-17.12
IV Loop Diuretics (LD)	-16.21

Weight at 72 hours after treatment initiation minus weight at treatment initiation. Negative mean values indicate weight loss. (NCT01474200)
Timeframe: 72 hours after treatment initiation

Length of Stay (LOS) During the Index Hospitalization

Intervention	lbs (Mean)
Aquapheresis (AQ) - Isolated Veno-venous Ultrafiltration	-10.69
IV Loop Diuretics (LD)	-10.30

Number of days patient is in hospital for HF treatment. (NCT01474200)
Timeframe: Index hospitalization admission to index hospitalization discharge

Mortality Rates Within Index Hospitalization or Within 90 Days After Hospital Discharge.

Intervention	Days (Mean)
Aquapheresis (AQ) - Isolated Veno-venous Ultrafiltration	8.49
IV Loop Diuretics (LD)	7.19

Death due to any cause within index hospitalization and 90 days following hospital discharge. (NCT01474200)
Timeframe: Time from randomization to 90 days post-hospital discharge

Time to First Heart Failure (HF) Event

Intervention	Percentage of Participants (Number)
Aquapheresis (AQ) - Isolated Veno-venous Ultrafiltration	15.45
IV Loop Diuretics (LD)	12.61

"Time to first HF event within 90 days after discharge from index HF hospitalization. HF events are defined as~HF rehospitalization or~unscheduled outpatient or emergency room treatment with IV loop diuretics or~unscheduled outpatient Aquapheresis treatment" (NCT01474200)
Timeframe: 90 days after discharge from index HF hospitalization.

CLINICAL: All Cause Rehospitalization Rates at 30 and 90 Days

Intervention	Days (Median)
Aquapheresis (AQ) - Isolated Veno-venous Ultrafiltration	62
IV Loop Diuretics (LD)	34

Any cause that required hospitalization for treatment within 90 days of index hospitalization discharge. (NCT01474200)
Timeframe: Within 30 days and 90 days after hospital discharge

CLINICAL: Global Clinical Score at 30 and 90 Days After Discharge

Intervention	Rehospitalizations/100 Pt-Days at Risk (Number)
	30 days after discharge	90 days after discharge
Aquapheresis (AQ) - Isolated Veno-venous Ultrafiltration	0.899	1.109
IV Loop Diuretics (LD)	1.278	1.237

KCCQ Questionnaire analysis based on patient's self-assessment of how they feel at various intervals compared to how they felt prior to index treatment. Scores were transformed to a range of 0-100, in which higher scores reflect better health status. (NCT01474200)
Timeframe: Within 90 days after hospital discharge

CLINICAL: Total Number of Cardiovascular (CV) Rehospitalizations at 30 and 90 Days After Discharge

Intervention	Scores on a Scale (Mean)
	Baseline	30 days after discharge	90 days after discharge
Aquapheresis (AQ) - Isolated Veno-venous Ultrafiltration	28.26	54.78	57.21
IV Loop Diuretics (LD)	31.83	53.08	60.56

CV symptoms that required hospitalization for treatment within 90 days of index hospitalization discharge. (NCT01474200)
Timeframe: Within 30 days and 90 days after hospital discharge

CLINICAL: Total Number of Days for Cardiovascular (CV) Rehospitalizations at 30 and 90 Days After Discharge

Intervention	Rehospitalizations (Number)
	30 days after discharge	90 days after discharge
Aquapheresis (AQ) - Isolated Veno-venous Ultrafiltration	17	46
IV Loop Diuretics (LD)	33	66

The total number of days spent in the hospital due to CV related events at 30 days and 90 days from hospital discharge. (NCT01474200)
Timeframe: Within 30 days and 90 days after hospital discharge

CLINICAL: Total Number of Days Rehospitalized for Heart Failure (HF) at 30 and 90 Days After Discharge

Intervention	Days (Number)
	30 days after discharge	90 days after discharge
Aquapheresis (AQ) - Isolated Veno-venous Ultrafiltration	88	377
IV Loop Diuretics (LD)	207	554

Days rehospitalized for HF symptoms requiring hospital, emergency room or clinic treatment involving the use of IV diuretics and /or positive inotropic or vasodilator drugs. (NCT01474200)
Timeframe: Within 30 days and 90 days after hospital discharge

CLINICAL: Total Number of Emergency Department (ED) or Unscheduled Office Visits at 30 and 90 Days After Discharge

Intervention	Days (Number)
	30 days after discharge	90 days after discharge
Aquapheresis (AQ) - Isolated Veno-venous Ultrafiltration	68	338
IV Loop Diuretics (LD)	172	460

Number of visits for HF symptoms requiring ED or clinic treatment involving the use of IV diuretics and /or positive inotropic or vasodilator drugs (NCT01474200)
Timeframe: Within 30 days and 90 days after hospital discharge

CLINICAL: Total Number of Heart Failure (HF) Rehospitalizations at 30 and 90 Days After Discharge

Intervention	Visits (Number)
	30 days after discharge	90 days after discharge
Aquapheresis (AQ) - Isolated Veno-venous Ultrafiltration	4	7
IV Loop Diuretics (LD)	5	8

Number of different times patient was admitted to hospital for HF symptoms within 90 days of index hospitalization discharge. (NCT01474200)
Timeframe: Within 30 days and 90 days after hospital discharge

Days Alive and Out of Hospital at 30 and 90 Days After Discharge

Intervention	Rehospitalizations (Number)
	30 days after discharge	90 days after discharge
Aquapheresis (AQ) - Isolated Veno-venous Ultrafiltration	11	36
IV Loop Diuretics (LD)	24	52

Number of days patients were alive and out of the hospital at 30 and 90 days after discharge. (NCT01474200)
Timeframe: Within 30 and 90 days after hospital discharge

EFFICACY: Changes in B-type Natriuretic Peptide (BNP) Levels Over Time

Intervention	Days (Mean)
	30 days after discharge	90 days after discharge
Aquapheresis (AQ) - Isolated Veno-venous Ultrafiltration	27.29	62
IV Loop Diuretics (LD)	26.46	61.38

Change in BNP levels over time at 72 hours, discharge, and 90 days after discharge. (NCT01474200)
Timeframe: Baseline and at 72 hours from baseline, hospital discharge and at 90 days after hospital discharge

Quality of Life Assessed Using the Kansas City Cardiomyopathy Questionnaire (KCCQ) at 30, 60 and 90 Days After Discharge

Intervention	pg/mL (Mean)
	Baseline	72 hours from baseline	Discharge	90 days after discharge
Aquapheresis (AQ) - Isolated Veno-venous Ultrafiltration	814.0	-169.8	-250.2	-159.9
IV Loop Diuretics (LD)	904.1	-120.5	-219.1	-201.3

Questionnaire assessed patients quality of life prior to index treatment versus timeframes following hospital discharge. Scores were transformed to a range of 0-100, in which higher scores reflect better health status. (NCT01474200)
Timeframe: Within 90 days after hospital discharge

SAFETY: Changes in Renal Function (Blood Urea Nitrogen) After Treatment up to 90 Days After Randomization

Intervention	Scores on a Scale (Mean)
	Baseline	30 days after discharge	90 days after discharge
Aquapheresis (AQ) - Isolated Veno-venous Ultrafiltration	25.39	52.06	59.72
IV Loop Diuretics (LD)	28.64	49.36	58.50

Changes in renal function prior to index treatment compared to various intervals by assessing the patient's serum creatinine (sCr), Blood Urea Nitrogen(BUN), BUN/sCr ratio and estimated glomerular filtration rate (eGFR) using the Modification of Diet in Renal Disease (MDRD) formula (NCT01474200)
Timeframe: Within 90 days of randomization

SAFETY: Changes in Renal Function (Blood Urea Nitrogen/Serum Creatinine) After Treatment up to 90 Days After Randomization

Intervention	mg/dL (Mean)
	Discharge	30 days after discharge	60 days after discharge	90 days after discharge
Aquapheresis (AQ) - Isolated Veno-venous Ultrafiltration	8.38	1.72	1.85	2.50
IV Loop Diuretics (LD)	7.62	6.56	3.16	-3.78

SAFETY: Changes in Renal Function (Estimated Glomerular Filtration Rate) After Treatment up to 90 Days After Randomization

Intervention	mg/dL (Mean)
	Discharge	30 days after discharge	60 days after discharge	90 days after discharge
Aquapheresis (AQ) - Isolated Veno-venous Ultrafiltration	3.77	0.28	0.07	5.66
IV Loop Diuretics (LD)	3.03	1.65	1.97	1.72

SAFETY: Changes in Renal Function (Serum Creatinine) After Treatment up to 90 Days After Randomization

Intervention	mL/min/1.73m2 (Mean)
	Discharge	30 days after discharge	60 days after discharge	90 days after discharge
Aquapheresis (AQ) - Isolated Veno-venous Ultrafiltration	-2.31	-0.56	-2.49	5.70
IV Loop Diuretics (LD)	-2.68	-3.33	2.15	7.41

Article	Year
Endothelial Dysfunction in Primary Aldosteronism. International journal of molecular sciences, 2019, Oct-21, Volume: 20, Issue:20 Topics: Aldosterone; Cardiovascular Diseases; Cerebrovascular Disorders; Disease Progression; Humans; Hypera	2019
Hypokalemia and the Prevalence of Primary Aldosteronism. Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme, 2020, Volume: 52, Issue:6 Topics: Adrenal Cortex Neoplasms; Adrenocortical Adenoma; Aldosterone; Disease Progression; Humans; Hyperald	2020
When should we start and stop ACEi/ARB in paediatric chronic kidney disease? Pediatric nephrology (Berlin, Germany), 2021, Volume: 36, Issue:7 Topics: Aldosterone; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antihyperte	2021
Retarding progression of chronic kidney disease: use of modalities that counter acid retention. Current opinion in nephrology and hypertension, 2018, Volume: 27, Issue:2 Topics: Acid-Base Imbalance; Aldosterone; Angiotensin II; Animals; Buffers; Citrates; Dietary Proteins; Dise	2018
Mineralocorticoid receptors in vascular disease: connecting molecular pathways to clinical implications. Current atherosclerosis reports, 2013, Volume: 15, Issue:7 Topics: Aldosterone; Animals; Atherosclerosis; Blood Pressure; Cardiovascular Diseases; Disease Progression;	2013
Mineralocorticoid Receptor Antagonists in End-Stage Renal Disease: Efficacy and Safety. Blood purification, 2016, Volume: 41, Issue:1-3 Topics: Aldosterone; Blood Pressure; Disease Progression; Eplerenone; Heart Failure; Humans; Kidney Failure,	2016
Aldosterone and progression of kidney disease. Therapeutic advances in cardiovascular disease, 2009, Volume: 3, Issue:2 Topics: Aldosterone; Animals; Chronic Disease; Clinical Trials as Topic; Disease Models, Animal; Disease Pro	2009
Role of aldosterone in the progression of chronic kidney disease and potential use of aldosterone blockade in children. Pediatric nephrology (Berlin, Germany), 2009, Volume: 24, Issue:12 Topics: Aldosterone; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Anim	2009
[Aldosterone block in proteinuria]. Nederlands tijdschrift voor geneeskunde, 2009, Apr-11, Volume: 153, Issue:15 Topics: Aldosterone; Angiotensin-Converting Enzyme Inhibitors; Disease Progression; Humans; Kidney Diseases;	2009
Aldosterone in the pathogenesis of chronic kidney disease and proteinuria. Current hypertension reports, 2010, Volume: 12, Issue:4 Topics: Aldosterone; Disease Progression; Glomerular Filtration Rate; Humans; Kidney Failure, Chronic; Miner	2010
[Non-steroidal anti-inflammatory drugs and risk of stroke in older patients: current controversies and research directions]. Giornale italiano di cardiologia (2006), 2011, Volume: 12, Issue:5 Topics: Age Factors; Aged; Aged, 80 and over; Aldosterone; Anti-Inflammatory Agents, Non-Steroidal; Atherosc	2011
Aldosterone, mineralocorticoid receptor and the metabolic syndrome: role of the mineralocorticoid receptor antagonists. Current vascular pharmacology, 2012, Volume: 10, Issue:2 Topics: Aldosterone; Animals; Cardiovascular Diseases; Disease Progression; Endothelium, Vascular; Humans; I	2012
Aldosterone blockade and the mineralocorticoid receptor in the management of chronic kidney disease: current concepts and emerging treatment paradigms. Kidney international, 2012, Volume: 81, Issue:10 Topics: Aldosterone; Animals; Chelating Agents; Combined Modality Therapy; Disease Progression; Humans; Hype	2012
Aldosterone in renal disease. Current opinion in nephrology and hypertension, 2003, Volume: 12, Issue:2 Topics: Aldosterone; Angiotensin-Converting Enzyme Inhibitors; Animals; Chronic Disease; Clinical Trials as	2003
Improving clinical outcomes with drug treatment in heart failure: what have trials taught? The American journal of cardiology, 2003, Mar-20, Volume: 91, Issue:6A Topics: Adrenergic beta-Antagonists; Aldosterone; Angiotensin-Converting Enzyme Inhibitors; Anti-Arrhythmia	2003
Neurohormone activation. Critical care nursing clinics of North America, 2003, Volume: 15, Issue:4 Topics: Aldosterone; Disease Progression; Heart Failure; Humans; Natriuretic Peptides; Neurotransmitter Agen	2003
Aldosterone in the development and progression of renal injury. Kidney international, 2004, Volume: 66, Issue:1 Topics: Aldosterone; Animals; Disease Progression; Humans; Kidney Diseases	2004
Aldosterone blockade: an emerging strategy for abrogating progressive renal disease. The American journal of medicine, 2006, Volume: 119, Issue:11 Topics: Aldosterone; Algorithms; Disease Progression; Disease Susceptibility; Drug Labeling; Eplerenone; Fib	2006
Metabolic alkalosis, bedside and bench. Seminars in nephrology, 2006, Volume: 26, Issue:6 Topics: Aldosterone; Alkalosis; Angiotensins; Animals; Biological Transport; Disease Progression; Endothelin	2006
Ca2+ channel subtypes and pharmacology in the kidney. Circulation research, 2007, Feb-16, Volume: 100, Issue:3 Topics: Aldosterone; Animals; Antihypertensive Agents; Arterioles; Blood Pressure; Calcium Channel Blockers;	2007
Vascular inflammation in hypertension and diabetes: molecular mechanisms and therapeutic interventions. Clinical science (London, England : 1979), 2007, Volume: 112, Issue:7 Topics: Aldosterone; Angiotensin II; Cell Adhesion Molecules; Cytokines; Diabetes Complications; Diabetes Me	2007
Natriuretic peptides and remodeling in heart failure. Heart failure clinics, 2005, Volume: 1, Issue:1 Topics: Aldosterone; Animals; Cardiotonic Agents; Disease Progression; Dose-Response Relationship, Drug; End	2005
Aldosterone and progression of renal disease. Current opinion in nephrology and hypertension, 2008, Volume: 17, Issue:1 Topics: Aldosterone; Animals; Disease Progression; Humans; Hypertension; Kidney Diseases; Prorenin Receptor;	2008
Rapid non-genomic effects of aldosterone on the renal vasculature. Steroids, 2008, Volume: 73, Issue:9-10 Topics: Aldosterone; Animals; Blood Flow Velocity; Disease Progression; Endothelium, Vascular; Glomerular Fi	2008
A clinical approach in regression of glomerulosclerosis. Romanian journal of internal medicine = Revue roumaine de medecine interne, 2007, Volume: 45, Issue:2 Topics: Aldosterone; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme	2007
Aldosterone is a major factor in the progression of renal disease. Kidney international. Supplement, 1997, Volume: 63 Topics: Aldosterone; Animals; Disease Progression; Humans; Kidney Diseases; Renin-Angiotensin System; Risk F	1997
Aldosterone and the hypertensive kidney: its emerging role as a mediator of progressive renal dysfunction: a paradigm shift. Journal of hypertension, 2001, Volume: 19, Issue:5 Topics: Aldosterone; Animals; Disease Progression; Humans; Hypertension; Kidney; Kidney Diseases; Renal Insu	2001
Aldosterone as a mediator of progressive renal dysfunction: evolving perspectives. Internal medicine (Tokyo, Japan), 2001, Volume: 40, Issue:7 Topics: Aldosterone; Animals; Clinical Trials as Topic; Disease Progression; Humans; Incidence; Kidney Failu	2001
The neurohormonal natural history of essential hypertension: towards primary or tertiary aldosteronism? Journal of hypertension, 2002, Volume: 20, Issue:1 Topics: Aldosterone; Cytochrome P-450 CYP11B2; Disease Progression; Humans; Hyperaldosteronism; Hypertension	2002

Article	Year
Evidence of primary aldosteronism in a predominantly female cohort of normotensive individuals: a very high odds ratio for progression into arterial hypertension. The Journal of clinical endocrinology and metabolism, 2013, Volume: 98, Issue:4 Topics: Adult; Aged; Aldosterone; Blood Pressure; Case-Control Studies; Cohort Studies; Dexamethasone; Diagn	2013
25 (OH) vitamin D levels and renal disease progression in patients with type 2 diabetic nephropathy and blockade of the renin-angiotensin system. Clinical journal of the American Society of Nephrology : CJASN, 2013, Volume: 8, Issue:11 Topics: Aged; Aldosterone; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors	2013
Angiotensin blockade in late autosomal dominant polycystic kidney disease. The New England journal of medicine, 2014, Dec-11, Volume: 371, Issue:24 Topics: Adolescent; Adult; Albuminuria; Aldosterone; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Co	2014
Effect of pentoxifylline in addition to losartan on proteinuria and GFR in CKD: a 12-month randomized trial. American journal of kidney diseases : the official journal of the National Kidney Foundation, 2008, Volume: 52, Issue:3 Topics: Aldosterone; Angiotensin II Type 1 Receptor Blockers; Blood Glucose; Blood Pressure; Chemokine CCL2;	2008
Rationale and design of the 'aldosterone receptor blockade in diastolic heart failure' trial: a double-blind, randomized, placebo-controlled, parallel group study to determine the effects of spironolactone on exercise capacity and diastolic function in pa European journal of heart failure, 2010, Volume: 12, Issue:8 Topics: Aldosterone; Diastole; Disease Progression; Diuretics; Double-Blind Method; Exercise Tolerance; Heal	2010
Combined converting enzyme inhibition and angiotensin receptor blockade reduce proteinuria greater than converting enzyme inhibition alone: insights into mechanism. Clinical nephrology, 2003, Volume: 60, Issue:1 Topics: Adult; Aged; Aged, 80 and over; Aldosterone; Angiotensin-Converting Enzyme Inhibitors; Disease Progr	2003
Diuretic use, progressive heart failure, and death in patients in the Studies Of Left Ventricular Dysfunction (SOLVD). Journal of the American College of Cardiology, 2003, Aug-20, Volume: 42, Issue:4 Topics: Aged; Aldosterone; Cause of Death; Disease Progression; Diuretics; Female; Heart Failure; Hospitaliz	2003
Diuretic use, progressive heart failure, and death in patients in the Studies Of Left Ventricular Dysfunction (SOLVD). Journal of the American College of Cardiology, 2003, Aug-20, Volume: 42, Issue:4 Topics: Aged; Aldosterone; Cause of Death; Disease Progression; Diuretics; Female; Heart Failure; Hospitaliz	2003
Diuretic use, progressive heart failure, and death in patients in the Studies Of Left Ventricular Dysfunction (SOLVD). Journal of the American College of Cardiology, 2003, Aug-20, Volume: 42, Issue:4 Topics: Aged; Aldosterone; Cause of Death; Disease Progression; Diuretics; Female; Heart Failure; Hospitaliz	2003
Diuretic use, progressive heart failure, and death in patients in the Studies Of Left Ventricular Dysfunction (SOLVD). Journal of the American College of Cardiology, 2003, Aug-20, Volume: 42, Issue:4 Topics: Aged; Aldosterone; Cause of Death; Disease Progression; Diuretics; Female; Heart Failure; Hospitaliz	2003
Baseline characteristics of patients recruited in the AREA IN-CHF study (Antiremodelling Effect of Aldosterone Receptors Blockade with Canrenone in Mild Chronic Heart Failure). Journal of cardiovascular medicine (Hagerstown, Md.), 2007, Volume: 8, Issue:9 Topics: Aged; Aldosterone; Biomarkers; Canrenone; Disease Progression; Double-Blind Method; Echocardiography	2007
Effect of angiotensin-converting enzyme and calcium channel inhibition on progression of IgA nephropathy. Contributions to nephrology, 1995, Volume: 111 Topics: Aldosterone; Blood Pressure; Combined Modality Therapy; Diet, Sodium-Restricted; Disease Progression	1995
Phase II study of vorozole (R83842), a new aromatase inhibitor, in postmenopausal women with advanced breast cancer in progression on tamoxifen. Clinical cancer research : an official journal of the American Association for Cancer Research, 1995, Volume: 1, Issue:3 Topics: Aged; Aged, 80 and over; Aldosterone; Androgens; Antineoplastic Agents; Aromatase Inhibitors; Breast	1995
Clinical and neurohormonal effects of nicardipine hydrochloride in patients with severe chronic heart failure receiving angiotensin-converting enzyme inhibitor therapy. American journal of therapeutics, 1998, Volume: 5, Issue:1 Topics: Aged; Aldosterone; Angiotensin-Converting Enzyme Inhibitors; Calcium Channel Blockers; Captopril; Ca	1998

Article	Year
Aldosterone in chronic kidney disease and renal outcomes. European heart journal, 2022, 10-11, Volume: 43, Issue:38 Topics: Aldosterone; Diabetes Mellitus; Disease Progression; Glomerular Filtration Rate; Humans; Kidney; Min	2022
Effects of renin-angiotensin-aldosterone-system inhibitors on coronary atherosclerotic plaques: The PARADIGM registry. Atherosclerosis, 2023, Volume: 383 Topics: Aldosterone; Angiotensins; Computed Tomography Angiography; Coronary Angiography; Coronary Artery Di	2023
Mechanisms of Metabolic Acidosis-Induced Kidney Injury in Chronic Kidney Disease. Journal of the American Society of Nephrology : JASN, 2020, Volume: 31, Issue:3 Topics: Acid-Base Equilibrium; Acidosis; Adaptation, Physiological; Aldosterone; Angiotensin II; Biomarkers;	2020
The Impact of Glucocorticoid Co-Secretion in Primary Aldosteronism on Thyroid Autoantibody Titers During the Course of Disease. Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme, 2020, Volume: 52, Issue:6 Topics: Adult; Aged; Aldosterone; Autoantibodies; Cohort Studies; Disease Progression; Female; Germany; Gluc	2020
Quantitative Value of Aldosterone-Renin Ratio for Detection of Aldosterone-Producing Adenoma: The Aldosterone-Renin Ratio for Primary Aldosteronism (AQUARR) Study. Journal of the American Heart Association, 2017, May-21, Volume: 6, Issue:5 Topics: Adrenocortical Adenoma; Aldosterone; Biomarkers, Tumor; Blood Pressure; Disease Progression; Female;	2017
Prevalence of primary aldosteronism without hypertension in the general population: Results in Shika study. Clinical and experimental hypertension (New York, N.Y. : 1993), 2018, Volume: 40, Issue:2 Topics: Adult; Aged; Aldosterone; Blood Pressure; Disease Progression; Female; Humans; Hyperaldosteronism; H	2018
Optimal follow-up strategies for adrenal incidentalomas: reappraisal of the 2016 ESE-ENSAT guidelines in real clinical practice. European journal of endocrinology, 2017, Volume: 177, Issue:6 Topics: Adrenal Gland Neoplasms; Adult; Aftercare; Aged; Aldosterone; Cohort Studies; Cushing Syndrome; Diag	2017
Triple-A syndrome: a wide spectrum of adrenal dysfunction. European journal of endocrinology, 2018, Volume: 178, Issue:3 Topics: Adolescent; Adrenal Insufficiency; Adrenocorticotropic Hormone; Adult; Aged; Aldosterone; Child; Cog	2018
Circulating α-Klotho is Related to Plasma Aldosterone and Its Follow-Up Change Predicts CKD Progression. Kidney & blood pressure research, 2018, Volume: 43, Issue:3 Topics: Aldosterone; Disease Progression; Follow-Up Studies; Glomerular Filtration Rate; Glucuronidase; Huma	2018
Relation of multi-marker panel to incident chronic kidney disease and rapid kidney function decline in African Americans: the Jackson Heart Study. BMC nephrology, 2018, 09-20, Volume: 19, Issue:1 Topics: Adiponectin; Aldosterone; Biomarkers; Black or African American; C-Reactive Protein; Disease Progres	2018
Modulation of aldosterone levels by aldosterone synthase promoter polymorphism and association with eGFR decline in patients with chronic kidney disease. Discovery medicine, 2018, Volume: 26, Issue:145 Topics: Adult; Aged; Aldosterone; Cardiovascular Diseases; Cerebrovascular Disorders; Cytochrome P-450 CYP11	2018
The Aldosterone/Renin Ratio Predicts Cardiometabolic Disorders in Subjects Without Classic Primary Aldosteronism. American journal of hypertension, 2019, 04-22, Volume: 32, Issue:5 Topics: Adult; Aldosterone; Biomarkers; Blood Pressure; Cross-Sectional Studies; Disease Progression; Female	2019
Serum Aldosterone as Predictor of Progression of Coronary Heart Disease in Patients Without Signs of Heart Failure After Acute Myocardial Infarction. Medical archives (Sarajevo, Bosnia and Herzegovina), 2018, Volume: 72, Issue:6 Topics: Aged; Aldosterone; Biomarkers; Coronary Disease; Disease Progression; Female; Follow-Up Studies; Hum	2018
Transthoracic Pulmonary Artery Denervation for Pulmonary Arterial Hypertension. Arteriosclerosis, thrombosis, and vascular biology, 2019, Volume: 39, Issue:4 Topics: Adolescent; Aldosterone; Animals; Child, Preschool; Cytokines; Disease Progression; Female; Fibrosis	2019
Aldosterone induced up-expression of ICAM-1 and ET-1 in pancreatic islet endothelium may associate with progression of T2D. Biochemical and biophysical research communications, 2019, 05-14, Volume: 512, Issue:4 Topics: Aldosterone; Animals; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Disease Progressio	2019
The decrease of mineralcorticoid receptor drives angiogenic pathways in colorectal cancer. PloS one, 2013, Volume: 8, Issue:3 Topics: Adenocarcinoma; Aldosterone; Biomarkers, Tumor; Cell Hypoxia; Colorectal Neoplasms; Disease Progress	2013
Renal sympathetic denervation suppresses ventricular substrate remodelling in a canine high-rate pacing model. EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology, 2014, Volume: 10, Issue:3 Topics: Aldosterone; Angiotensin II; Animals; Arrhythmias, Cardiac; Cardiac Pacing, Artificial; Catheter Abl	2014
Effects of adiponectin on calcium-handling proteins in heart failure with preserved ejection fraction. Circulation. Heart failure, 2014, Volume: 7, Issue:6 Topics: Adiponectin; Aldosterone; Animals; Calcium; Calcium-Binding Proteins; Calmodulin; Cyclic AMP-Depende	2014
Impaired epithelial Na+ channel activity contributes to cystogenesis and development of autosomal recessive polycystic kidney disease in PCK rats. Pediatric research, 2015, Volume: 77, Issue:1-1 Topics: Aldosterone; Amiloride; Animals; Aquaporin 2; Disease Models, Animal; Disease Progression; Epithelia	2015
DACH1, a zona glomerulosa selective gene in the human adrenal, activates transforming growth factor-β signaling and suppresses aldosterone secretion. Hypertension (Dallas, Tex. : 1979), 2015, Volume: 65, Issue:5 Topics: Adrenocortical Carcinoma; Aldosterone; Disease Progression; Eye Proteins; Female; Gene Expression Re	2015
Long-term treatment with aldosterone slows the progression of age-related hearing loss. Hearing research, 2016, Volume: 336 Topics: Aging; Aldosterone; Animals; Auditory Threshold; Blood Pressure; Cognition; Disease Progression; Ele	2016
Altered relation of the renin-aldosterone system and vasoactive peptides in type 2 diabetes: The KORA F4 study. Atherosclerosis, 2016, Volume: 252 Topics: Adrenomedullin; Adult; Aged; Aldosterone; Anthropometry; Biomarkers; Carotid Arteries; Carotid Intim	2016
Aldosterone, hypertension, and cardiovascular disease: an endless story. Hypertension (Dallas, Tex. : 1979), 2008, Volume: 52, Issue:2 Topics: Aldosterone; Cardiovascular Diseases; Chronic Disease; Comorbidity; Disease Progression; Female; Hum	2008
Conventional therapy with an ACE inhibitor diminishes left ventricular dyssynchrony during the progression of heart failure. International journal of cardiology, 2010, Apr-01, Volume: 140, Issue:1 Topics: Aldosterone; Angiotensin II; Angiotensin-Converting Enzyme Inhibitors; Animals; Comorbidity; Disease	2010
Aldosterone receptor inhibition alters the viscoelastic biomechanical behavior of the aortic wall. Experimental biology and medicine (Maywood, N.J.), 2010, Volume: 235, Issue:3 Topics: Aldosterone; Animals; Aorta; Biomechanical Phenomena; Blood Pressure; Disease Progression; Elasticit	2010
Selective aldosterone blocker ameliorates the progression of non-alcoholic steatohepatitis in rats. International journal of molecular medicine, 2010, Volume: 26, Issue:3 Topics: Aldosterone; Animals; Disease Progression; Fatty Liver; Liver Cirrhosis; Liver Neoplasms; Male; Rats	2010
Potential benefits of alkali therapy to prevent GFR loss: time for a palatable 'solution' for the management of CKD. Kidney international, 2010, Volume: 78, Issue:11 Topics: Acid-Base Equilibrium; Acidosis; Administration, Oral; Aldosterone; Animals; Bicarbonates; Chronic D	2010
Adrenal beta-arrestin 1 inhibition in vivo attenuates post-myocardial infarction progression to heart failure and adverse remodeling via reduction of circulating aldosterone levels. Journal of the American College of Cardiology, 2011, Jan-18, Volume: 57, Issue:3 Topics: Adrenal Glands; Aldosterone; Animals; Arrestins; beta-Arrestin 1; beta-Arrestins; Cell Line; Disease	2011
Impact of aldosterone synthase gene C-344T polymorphism on IgA nephropathy. Renal failure, 2011, Volume: 33, Issue:4 Topics: Adult; Aldosterone; Biopsy; Cytochrome P-450 CYP11B2; Disease Progression; Female; Genotype; Glomeru	2011
Endothelial progenitor cells in primary aldosteronism: a biomarker of severity for aldosterone vasculopathy and prognosis. The Journal of clinical endocrinology and metabolism, 2011, Volume: 96, Issue:10 Topics: Adenoma; Adult; Aged; Aldosterone; Apoptosis; Arteries; Biomarkers; C-Reactive Protein; Cell Count;	2011
Long-term mineralocorticoid receptor blockade ameliorates progression of experimental diabetic renal disease. Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, 2012, Volume: 27, Issue:3 Topics: Aldosterone; Animals; Blood Pressure; Blotting, Western; Collagen Type IV; Diabetes Mellitus, Experi	2012
Chronic antagonism of the mineralocorticoid receptor ameliorates hypertension and end organ damage in a rodent model of salt-sensitive hypertension. Clinical and experimental hypertension (New York, N.Y. : 1993), 2011, Volume: 33, Issue:8 Topics: Aldosterone; Animals; Blood Pressure; Chronic Disease; Creatinine; Disease Models, Animal; Disease P	2011
Interferon-γ ablation exacerbates myocardial hypertrophy in diastolic heart failure. American journal of physiology. Heart and circulatory physiology, 2012, Sep-01, Volume: 303, Issue:5 Topics: Aldosterone; Animals; Autophagy; Disease Models, Animal; Disease Progression; Fibrosis; Heart Failur	2012
Inhibition of brain angiotensin III attenuates sympathetic hyperactivity and cardiac dysfunction in rats post-myocardial infarction. Cardiovascular research, 2013, Mar-01, Volume: 97, Issue:3 Topics: Aldosterone; Angiotensin III; Animals; Baroreflex; Blood Pressure; Brain; Disease Models, Animal; Di	2013
The epithelial Na+ channel: progressing from Liddle's syndrome to essential hypertension. Journal of hypertension, 2003, Volume: 21, Issue:5 Topics: Aldosterone; Black People; Disease Progression; Genetic Predisposition to Disease; Humans; Hypertens	2003
Disorders of sex hormone status in patients with chronic obstructive pulmonary disease. Wiadomosci lekarskie (Warsaw, Poland : 1960), 2003, Volume: 56, Issue:3-4 Topics: Adult; Age Factors; Aldosterone; Case-Control Studies; Disease Progression; Estradiol; Follicle Stim	2003
Aldosteronism and peripheral blood mononuclear cell activation: a neuroendocrine-immune interface. Circulation research, 2003, Nov-14, Volume: 93, Issue:10 Topics: Aldosterone; Animals; Calcium; Cell Separation; Coronary Vessels; Disease Models, Animal; Disease Pr	2003
Aldosterone levels after angiotensin receptor blocker treatment. Circulation, 2004, Apr-13, Volume: 109, Issue:14 Topics: Aldosterone; Angiotensin II Type 1 Receptor Blockers; Disease Progression; Heart Failure; Humans; Te	2004
Adrenomedullin administration immediately after myocardial infarction ameliorates progression of heart failure in rats. Circulation, 2004, Jul-27, Volume: 110, Issue:4 Topics: Adrenomedullin; Aldosterone; Animals; Body Weight; Dinoprost; Disease Progression; Drug Evaluation,	2004
Can young adult patients with proteinuric IgA nephropathy perform physical exercise? American journal of kidney diseases : the official journal of the National Kidney Foundation, 2004, Volume: 44, Issue:2 Topics: Adult; Aldosterone; Angiotensin-Converting Enzyme Inhibitors; Case-Control Studies; Creatinine; Dise	2004
Furosemide and the progression of left ventricular dysfunction in experimental heart failure. Journal of the American College of Cardiology, 2004, Sep-15, Volume: 44, Issue:6 Topics: Adrenergic beta-Agonists; Aldosterone; Animals; Biomarkers; Disease Models, Animal; Disease Progress	2004
Vasoactive mediators and retinopathy during type 1 diabetic pregnancy. Acta ophthalmologica Scandinavica, 2005, Volume: 83, Issue:1 Topics: Adrenomedullin; Adult; Aldosterone; Angiotensin II; Blood Flow Velocity; Diabetes Mellitus, Type 1;	2005
Aldosterone stimulates proliferation of mesangial cells by activating mitogen-activated protein kinase 1/2, cyclin D1, and cyclin A. Journal of the American Society of Nephrology : JASN, 2005, Volume: 16, Issue:8 Topics: 11-beta-Hydroxysteroid Dehydrogenase Type 2; Aldosterone; Animals; Blotting, Western; Cell Cycle; Ce	2005
Neuro-hormonal activation predicts ventilatory response to exercise and functional capacity in patients with heart failure. European journal of heart failure, 2006, Volume: 8, Issue:1 Topics: Aldosterone; Biomarkers; Disease Progression; Epinephrine; Exercise Test; Exercise Tolerance; Female	2006
Effect of prepuberal gonadectomy upon aldosterone levels in female and male SHR: interaction between blood pressure and kallikrein kinin system. Clinical and experimental hypertension (New York, N.Y. : 1993), 2006, Volume: 28, Issue:2 Topics: Aging; Aldosterone; Animals; Biomarkers; Blood Pressure; Castration; Disease Models, Animal; Disease	2006
Plasma levels of endothelin-1 at rest and after exercise in patients with moderate congestive heart failure. International journal of cardiology, 1995, Volume: 51, Issue:3 Topics: Adult; Aldosterone; Atrial Natriuretic Factor; Cardiomyopathy, Dilated; Disease Progression; Endothe	1995
Pathogenesis of edema formation in the nephrotic syndrome. Kidney international. Supplement, 1997, Volume: 58 Topics: Adolescent; Aldosterone; Atrial Natriuretic Factor; Blood Volume; Child; Child, Preschool; Disease P	1997
Aldosterone modulates plasminogen activator inhibitor-1 and glomerulosclerosis in vivo. Kidney international, 2000, Volume: 58, Issue:3 Topics: Aldosterone; Angiotensin II; Animals; Blood Pressure; Blotting, Northern; Creatinine; Disease Progre	2000
Epidemiology and pathophysiology of heart failure. Current cardiology reports, 2000, Volume: 2, Issue:3 Topics: Aldosterone; Angiotensin-Converting Enzyme Inhibitors; Clinical Trials as Topic; Disease Progression	2000
Serum aldosterone changes during hyperinsulinemia are correlated to body mass index and insulin sensitivity in patients with essential hypertension. Journal of hypertension, 2001, Volume: 19, Issue:1 Topics: Aldosterone; Biomarkers; Blood Glucose; Blood Pressure; Body Mass Index; Calcium; Disease Progressio	2001
Water metabolism disturbances at different stages of primary thyroid failure. The Journal of endocrinology, 2001, Volume: 168, Issue:3 Topics: Adolescent; Adult; Aged; Aldosterone; Analysis of Variance; Arginine Vasopressin; Disease Progressio	2001
Relationship between transcardiac extraction of aldosterone and left ventricular remodeling in patients with first acute myocardial infarction: extracting aldosterone through the heart promotes ventricular remodeling after acute myocardial infarction. Journal of the American College of Cardiology, 2001, Nov-01, Volume: 38, Issue:5 Topics: Acute Disease; Aged; Aldosterone; Angioplasty, Balloon, Coronary; Angiotensin-Converting Enzyme Inhi	2001

aldosterone and Disease Exacerbation